In a mouse xenograft model of lung cancer, the combination of PD-L1 blockade and Gal-3 inhibitor synergistically reduced tumor growth, which was accompanied by increased infiltration of CD3+ tumor-infiltrating lymphocytes (TILs) and granzyme B release into tumors [162]. Here, LGALS3 is linked to lung cancer.